Targeted therapy for renal cell cancer: current perspectives.

@article{Veldt2010TargetedTF,
  title={Targeted therapy for renal cell cancer: current perspectives.},
  author={Astrid A. M. van der Veldt and John B A G Haanen and Alfons J. M. van den Eertwegh and Epie Boven},
  journal={Discovery medicine},
  year={2010},
  volume={10 54},
  pages={394-405}
}
In the past 5 years, the introduction of targeted therapy has dramatically changed the outcome of patients with metastatic renal cell cancer (mRCC). In particular, drugs that inhibit signaling of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) have significantly improved the perspectives of patients with this chemoresistant disease. Here, we review the currently approved targeted drugs for the treatment of mRCC. We describe the anti-VEGF monoclonal antibody… CONTINUE READING
20 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…